Alfred Garfall, MD

Articles by Alfred Garfall, MD

Consolidation and Maintenance Therapy in Transplant-Eligible NDMM

ByAlfred Garfall, MD,Edward A. Stadtmauer, MD,Dan Vogl, MD,Sandara Susanibar-Adaniya, MD

November 4th 2022

A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.

Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma

ByAlfred Garfall, MD,Edward A. Stadtmauer, MD,Dan Vogl, MD,Sandara Susanibar-Adaniya, MD

November 4th 2022

Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.

Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM

ByAlfred Garfall, MD,Edward A. Stadtmauer, MD,Dan Vogl, MD,Sandara Susanibar-Adaniya, MD

October 28th 2022

Comprehensive insight on induction therapy regimens in transplant-eligible newly diagnosed multiple myeloma based on the GRIFFIN, MASTER, and DETERMINATION clinical studies.

Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

ByAlfred Garfall, MD,Edward A. Stadtmauer, MD,Dan Vogl, MD,Sandara Susanibar-Adaniya, MD

October 28th 2022

Expert panelists review the case of transplant-eligible newly diagnosed multiple myeloma and consider optimal selection of induction therapy.

Alfred Garfall, MD

Articles by Alfred Garfall, MD

Consolidation and Maintenance Therapy in Transplant-Eligible NDMM

Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM

Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

Trending on CancerNetwork

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Searching for Synergy in Liver-Dominant Neuroendocrine Tumors

Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC